98%
921
2 minutes
20
Background: Neurofibromatosis type 1 (NF1) is a genetic disease that alters neurodevelopment. We aimed to analyze the sleep macrostructure of a sample of children affected by NF1 without neurocognitive co-morbidities and MRI reports of unidentified bright objects (UBOs).
Methods: A 100 pre-pubertal children participated in the cross-sectional study: 50 subjects were children diagnosed with NF1 and 50 subjects were typically developing healthy children (TDC). All participants underwent polysomnographic evaluation through which conventional sleep parameters were collected: Total sleep time (TST), Sleep latency (SOL), first REM latency (FRL), number of stage shifts/h (SS/h), number of awakenings/h (AWN/h), wake after sleep onset (WASO%), sleep efficiency percentage (SE%), percentage of sleep time spent in sleep stages 1 (N1%) and 2 (N2%), slow-wave sleep (N3%), and REM sleep (REM%). Additionally, nocturnal respiratory events such as apnea/hypopnea index (AHI), oxygen desaturation index (ODI), and periodic limb movement index (PLMI) were recorded.
Results: Neurofibromatosis type 1 children showed a reduction in sleep duration parameters (TST; < 0.001), sleep efficiency (SE%; < 0.001), and stage N2% ( < 0.001). Moreover, the number of awakenings per hour (AWN/h), wake after sleep onset (WASO%), and respiratory events such as AHI, ODI, and PLMI resulted higher in NF1 vs. TDC children.
Conclusion: The data showed that the sleep macrostructure differs between NF1 and TDC children. These findings suggest that the evaluation of sleep may provide useful support in corroborating the diagnosis and offers additional therapeutic management perspectives in NF1 and genetic neurodevelopmental disorders in general.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10394094 | PMC |
http://dx.doi.org/10.3389/fneur.2023.1213430 | DOI Listing |
Neurosci Biobehav Rev
September 2025
Murdoch Children's Research Institute, Melbourne, Australia; Department of Pediatrics, University of Melbourne, Melbourne, Australia.
This systematic review was conducted to provide a comprehensive summary of biopsychosocial factors associated with attention-deficit/hyperactivity disorder (ADHD) in children and adolescents with Neurofibromatosis Type 1 (NF1), and identify key limitations and gaps in the current literature. Systematic literature searches were conducted in Scopus, PsycINFO, Web of Science, PubMed, and ProQuest Dissertations and Theses Global in March 2024. The searches identified 2,345 unique articles.
View Article and Find Full Text PDFJBJS Case Connect
July 2025
Department of Orthopaedics, All India Institute of Medical Sciences, Rishikesh, India.
Case: A 12-year-old girl with neurofibromatosis type 1 presented with progressive thoracic scoliosis and neurological deficit. Imaging revealed a dystrophic curve, dorsal syrinx, and tethering of the cord by a plexiform neurofibroma arising from the T7 dorsal ramus. She underwent staged surgery: detethering through T6-T8 laminectomy, followed by posterior spinal deformity correction with Schwab type 2 osteotomies and instrumentation.
View Article and Find Full Text PDFDev Med Child Neurol
September 2025
Murdoch Children's Research Institute, Parkville, VIC, Australia.
Aim: To examine visual engagement to social stimuli and response to joint attention in young children with neurofibromatosis type 1 (NF1) and typically developing peers (controls).
Method: Forty-five preschool children were studied cross-sectionally (mean age [SD] = 4 years 3 months [10 months]), 25 with NF1 and 20 typically developing controls. Participants passively viewed two eye-tracking paradigms.
Cancer Diagn Progn
September 2025
Institute of Neuropathology, Eppendorf University Hospital, University of Hamburg, Hamburg, Germany.
Background/aim: Neurofibromatosis type 1 (NF1) is a genetic disorder characterized by the development of multiple tumors, including plexiform neurofibromas (PNFs), which often affect the craniofacial region and cause significant functional and aesthetic impairments. This report presents long-term surgical management of a patient with hemifacial diffuse PNF, complicated by the emergence of a rapidly enlarging midfacial tumor.
Case Report: The patient was treated for hemifacial invasive diffuse plexiform neurofibroma.
Front Pharmacol
August 2025
Biochemistry, Pharmacology and Newborn Screening Unit, Central Laboratory of Analysis, IRCCS Istituto Giannina Gaslini, Genoa, Italy.
Neurofibromatosis type 1 (NF1) is a genetic disorder characterized by the development of plexiform neurofibromas (PNs), benign yet potentially debilitating tumors with limited treatment options. Selumetinib, a selective MEK1/2 inhibitor, has emerged as a targeted therapy for symptomatic, inoperable PNs in pediatric NF1 patients. Individual variability in drug metabolism, largely influenced by CYP450-mediated pathways, can affect treatment response.
View Article and Find Full Text PDF